Uridine monophosphate (UMP) has been investigated as a potential supportive treatment for Alzheimer's Disease (AD) based on its role in phospholipid synthesis and synaptic membrane formation. Several preclinical studies have demonstrated that uridine, especially when combined with choline and DHA (found in the medical food Souvenaid), can enhance synaptic formation and function in animal models of AD. These compounds act as precursors for the synthesis of phosphatidylcholine, a critical component of neuronal membranes, and may support synaptic health, which is compromised in AD.

Clinical evidence, however, remains limited and mixed. The most notable clinical studies involve Souvenaid, a nutritional supplement containing UMP, choline, and DHA. Some randomized controlled trials have reported modest benefits in memory performance in patients with mild AD, but these effects have not consistently translated to broader cognitive improvements or slowed disease progression. The individual contribution of UMP, as opposed to the combination of ingredients, is not well established. No major clinical guidelines recommend UMP as a primary or adjunct treatment for AD, and its use is considered experimental.

Therefore, while there is a plausible biological mechanism and some preclinical and small clinical studies suggesting potential benefit, the overall quality and quantity of evidence supporting UMP’s use in AD is low, justifying a rating of 2/5.